Veristat, Inc.'s Collaboration With Aegerion Pharmaceuticals, Inc. Contributes to FDA Approval of Juxtapid™

HOLLISTON, Mass.--(BUSINESS WIRE)--Veristat, a leading Clinical Research Organization (CRO), applauds Aegerion Pharmaceuticals on their recent FDA approval of Juxtapid for the treatment of patients with homozygous familial hypercholesterolemia (HoFH) (official press release.) Dr. John Balser, President of Veristat commented, “Congratulations to the Aegerion team. As a pivotal strategic partner on the biostatistical, medical writing, and regulatory strategy for this submission, we are honored to have played a part in the approval of such an important, lifesaving therapy.”